Kestra Medical Technologies (NASDAQ:KMTS) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a research report report published on Monday, Marketbeat reports. The firm issued an overweight rating and a $30.00 price target on the stock.

A number of other equities research analysts have also recently commented on the company. BTIG Research raised their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Oppenheimer initiated coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating on the stock. Wall Street Zen raised Kestra Medical Technologies from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research note on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Kestra Medical Technologies currently has an average rating of “Hold” and a consensus price target of $28.14.

Kestra Medical Technologies Stock Performance

KMTS opened at $28.00 on Monday. The company has a 50 day simple moving average of $23.49 and a two-hundred day simple moving average of $22.66. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. The firm has a market cap of $1.64 billion, a P/E ratio of -11.57 and a beta of 0.58. Kestra Medical Technologies has a 1-year low of $15.06 and a 1-year high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The firm had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. Equities analysts forecast that Kestra Medical Technologies will post -2.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Kestra Medical Technologies

In related news, insider Alfred J. Ford, Jr. sold 13,015 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $23.90, for a total value of $311,058.50. Following the sale, the insider directly owned 105,839 shares in the company, valued at approximately $2,529,552.10. The trade was a 10.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Traci S. Umberger sold 8,752 shares of the stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $22.60, for a total value of $197,795.20. Following the transaction, the insider directly owned 206,995 shares of the company’s stock, valued at approximately $4,678,087. The trade was a 4.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 238,164 shares of company stock worth $5,603,152. Insiders own 5.30% of the company’s stock.

Institutional Trading of Kestra Medical Technologies

Hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD increased its position in Kestra Medical Technologies by 137.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after purchasing an additional 2,529,851 shares during the last quarter. Brown Advisory Inc. lifted its position in Kestra Medical Technologies by 34.1% during the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after purchasing an additional 428,996 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of Kestra Medical Technologies by 13.7% in the 3rd quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock worth $35,449,000 after buying an additional 179,885 shares in the last quarter. Eventide Asset Management LLC grew its stake in shares of Kestra Medical Technologies by 5.4% in the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after buying an additional 65,288 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of Kestra Medical Technologies by 180.8% in the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock worth $25,221,000 after buying an additional 612,343 shares during the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.